Weight-loss drug Wegovy made Novo Nordisk Europe’s most valuable company. Finding its next blockbuster drug is proving difficult
A clinical trial failure and U.S. competition have been tough for the Danish pharmaceutical firm. CFO Karsten Munk Knudsen says the company is doubling down on innovation and its weight loss pills as it looks toward its next stage of growth.
Record details
Published: 6 August 2026
Source: Fortune AI
Category: News
Topics: Healthcare · Biotech
Retrieved: 7 August 2026
Related evidence
These records share source-supplied organisations, an exact publisher byline, automatic topics or regions. The reason is shown on every link; related does not mean supporting, agreeing with or verifying this record.
Big tech could reshape healthcare faster than regulators expect, warns MEP
Euractiv Digital · 14 August 2026
Open Joint Letter on the AI Act Regulating AI-embedded Medical Devices
Center for Democracy & Technology · 16 July 2026
Navigating the Global Regulatory Landscape for Exosome-Based Therapeutics: Challenges, Strategies, and Future Directions
OpenAlex · 30 July 2025
Portugal:: Health System review, 2017
OpenAlex · 1 March 2017
India’s drug regulator has not adopted AI for regulatory approvals: Govt
MediaNama (IN) · 6 August 2026
Google’s Top AI Brains Are Leaving to Launch Discovery Loop
Wired · 5 August 2026
How to cite this record
ethics.ai (6 August 2026), “Weight-loss drug Wegovy made Novo Nordisk Europe’s most valuable company. Finding its next blockbuster drug is proving difficult,” evidence record 17184, https://ethics.ai/record/17184 (originally published by Fortune AI).
Use and limitations
This page is a stable index and citation surface for a source record. ethics.ai did not author the underlying report and has not independently verified every claim. Automatic topics may be imperfect. For consequential use, quote and cite the original publisher.